ABSTRACT
Introduction
The cytochrome P-450 system (CYP) is responsible for the metabolism of several naturally occurring and synthetic compounds. The CYP2C9 isoenzyme is primarily responsible for the oxidative metabolism of several drugs, including warfarin, phenytoin, losartan, irbesartan, tolbutamide, glipizide, torsemide, and various nonsteroidal anti-inflammatory drugs [1] . Multiple single nucleotide polymorphisms within the gene for CYP2C9 have been identified, and at least 13 of these encode CYP2C9 alleles [2, 3] . Three alleles, CYP2C9*1, *2 and *3, are present in most ethnic populations. The most common allele is designated *1 and is considered the wild-type allele. The *2 allele results from a single base substitution (430 C > T) that is located in exon 3. The *3 (1075 A > C), *4 (1076 T > C), and *5 (1080 C > G) alleles result from base changes located in exon 7. In addition, some null polymorphisms have been recently identified except for CYP2C9*34 in Japanese population [3] . The *2 and *3 alleles encode a protein with reduced enzymatic activity in vitro, and patients with these alleles have been designnated as "poor metabolizers" [4, 5] , that may experience drug toxicity. Thus the dose of these drugs may need to be adjusted according to CYP2C9 genotype. The genotype distribution among individuals varies with ethnic background. In Caucasian populations, for example, approximately two thirds of individuals express the wildtype genotype, *1/*1; one third express the *1/*2 or *1/*3 genotype; and fewer than 2.5% express the *2/*2, *2/*3, or *3/*3 genotype [2] . The allele frequencies of CYP2C9*2 and CYP2C9*3 tend to be greater in Caucasians populations compared to African-American and Asian populations; the CYP2C9*2 was not found in East Asians including Chinese and Japanese [6] .
To our knowledge, there is little knowledge about genotyping of cytochrome P450s in the Middle East, and there has not been any report on the genotype of CYP2C9 allelic variants in Lebanese population who are considered White Caucasians. Lebanon is a small country of 10500 km 2 on the eastern shores of the Mediterranean Sea; it has made a historical crossroads between Asia, Africa, and Europe. Today, the population is approximately 4 million people, with a worldwide diaspora estimated at 16 million. Thus the purpose of the study was to determine the CYP2C9*1, CYP2C9*2, CYP2C9*3, CYP2C9*4, and CYP2C9*5, allele and genotype frequentcies in Lebanese and compare with other populations. The results will serve as baseline clinical data for dosing of drugs metabolised by CYP2C9 based on Lebanese patients' genotypes and avoiding the adverse drug reactions.
Materials and Methods

Subjects
A total of 146 healthy volunteers were recruited from the Lebanese population. All subjects signed a consent form. Included were non-obese subjects (body mass index (BMI)  29.5 Kg/m 2 ), with no history or clinical evidence of diabetes, cardiovascular problems, hypertension, renal insufficiency, and/or depression. All study subjects are of Lebanese origin, and were living in Lebanon at the time of study. The School of Pharmacy research committee approved the project.
CYP2C9*2*3*4*5 Gene Polymorphism Genotyping
Each volunteer was asked to give a DNA sample from the cheek using a cheek swab. DNA was isolated from cheek swabs by a method previously described [7] . Genotype polymorphisms for the CYP2C9*2,*3,*4, and *5 alleles was performed by means of PCR (MyCycler; BioRad laboratories, Hercules, Calif) followed by Pyrosequencing [8] by using PSQ HS 96A System (Biotage AB), with use of automated PSQ HS 96A SNP software (Biotage AB); a previously validated protocol [9] . In brief, the PCR reaction mixture used for target sequence amplification consisted of 13 μl of HotStarTaq Master Mix (Qiagen), 10 pmol of each primer (Invitrogen) (1 μlL), and 50 -100 ng (10 μl) of genomic DNA. Primer sequences are as detailed in Table 1 [10] . The PCR amplification was performed under the following conditions: initial denaturation at 95˚C for 15 minutes, 45 cycles of denaturation at 95˚C for 30 seconds, annealing at 55˚C for 30 seconds, and extension at 72˚C for 1 minute, followed by a final extension step at 72˚C for 7 minutes. As for the pysrosequencing analysis, 10 μl of bioti--nylated PCR product was immobilized to streptavidincoated Sepharose beads (Amersham Biosciences, Piscataway, NJ). After incubation, the beads were isolated and treated with 70% ethanol, denaturation buffer, and wash buffer. The beads then were released into designnated wells containing annealing buffer and 10 pmol of sequencing primer, followed by a 2-minute incubation at 80˚C. Reproducibility was assessed by analyzing 42 samples in duplicate DNA. Sequencing primer for *3,*4, and*5
5'-GCTGGTGGGGAGAAG-3'
F , forward; R, reverse; B, biotin labeled.
Statistical Analysis
Sample size was determined a priori by use of statistical power analysis with SAS software (SAS Institute, Cary, NC). Calculations revealed that a minimum of 120 samples is required for the genotype representation in the Lebanese population [11] . Statistical analyses were performed using the SigmaStat 3.5. The study samples alleles and genotype frequencies were estimated by gene counting method. The agreement with Hardy-Weinberg equilibrium of the observed genotypic distribution for the CYP2C9 gene was tested by chi-square tests. A P value of  0.05 was considered statistically significant. Population comparisons were also performed by Chi-square test of population differentiation.
Results
Subjects Demographic Characteristics
A total of 146 Lebanese subjects were included in the study, which aimed to determine the CYP2C9 
CYP2C9*1,*2,*3,*4, and *5 Gene Polymorphism Genotype Distribution in Lebanese and Hardy-Weinberg Equilibrium
The detailed distribution of the CYP2C9*2,*3,*4, and *5 genotypes in the Lebanese population is depicted in Table 2. The frequencies of the CYP2C29*2, CYP2C9*3, and CYP2C9*4 alleles were 11.31%, 9.59%, and 1.025% respectively. No CYP2C9*5 allele variants were found among the Lebanese study sample. Volunteers could be divided into three CYP2C9 genotypes groups: subjects (76.71%) with no variant alleles (CYP2C9*1*1; homozygous extensive metabolizers, EM), 21.23% with one variant allele (CYP2C9*1*2, *1*3, *1*4, and *1*5; heterozygous intermediate metabolizers IM), and 2.06% with two mutated alleles (such as CYP2C9 *2*2, *2*3, *3*3, *2*4, and other homozygous variants/ poor metabolisers, PM).
CYP2C9 allele and genotype frequencies did not deviate from Hardy-Weinberg equilibrium (P = 0.743, Fisher exact test).
Comparisons of population differentiation: CYP2C9 genotype frequencies in different populations as compared to those of Lebanese. The comparative analysis using genotype groups of different populations showed differences among Lebanese and other Caucasians ( Table 3 ).
Discussion
CYP2C9 polymorphisms give rise to inter-individual and interethnic variability in the metabolism and disposition of several therapeutic agents. CYP2C9 polymorphisms may cause differences in the clinical response to these drugs. CYP2C9 various forms include CYP2C9*1 (wild type) and two well-characterized SNPs, an arginine-tocysteine change at codon 144 (Arg144Cys, CYP2C9*2), and isoleucine-to-leucine change at codon 359 (Ile359-Leu, CYP2C9*3). CYP2C9*4 (an isoleucine-to-threonine change at codon 359 and CYP2C9*5 (an aspartic acid-toglutamic acid change at codon 360) as well as other polymorphisms have been also reported in different populations. Patients who have variant alleles of CYP2C9 require, for example, reduced maintenance doses of warfarin compared to those having wild type-alleles [12] . The *2/*2 homozygous variant leads to a reduction of approximately 12% of CYP2C9 activity and the *3/*3 homozygous variant has < 5% of wild type CYP2C9 activity [13] . The *2 and *3 alleles, have been associated with an increased risk of warfarin over anticoagulation and bleeding events [14] . Alternate genotypes composed of 1 or more low-activity alleles also may account for the difficult-to control anticoagulation status in some patients [15] . The accumulated evidence suggests that the CYP2C9 genotype has been used to develop warfarindosing algorithms to avoid the morbidity associated with over anticoagulation [10] . Earlier studies have indicated differences in CYP2C9 enzyme activity may exist not only between the major races but also among different Caucasians populations. Consequently, further studies on different Caucasian ethnic groups are needed to provide relevant genotypic data for each population. To our knowledge, this is the first study that reports different CYP2C9*2,*3,*4, and *5 genotypes in the Lebanese population (White Caucasians). Frequencies of CYP2C9 genotype polymorphisms resulted very high, showing a higher frequency of CYP 2C9 homozygous extensive metabolisers (*1/*1) compared to other Caucasians i.e., Southern Europe (Table  3) . Additionally, CYP2C9*5 allele frequency was not found among the Lebanese study sample.
The ability to determine a patient's genotype helps future pharmacogenomic investigations and the transition of pharmacogenomics into mainstream clinical practice. This feature is necessary for situations in which randomization, or the start of drug therapy, is dependent on genotype determinations.
In conclusion, CYP2C9 gene polymorphisms classified individuals mainly into extensive and intermediate metabolisers. This first report from Lebanon highlights a higher frequency of CYP2C9 extensive metabolisers compared to Europeans and North American Caucasians; a unique feature that serves a baseline clinical data for dosing of drugs metabolised by CYP 2C9 based on Lebanese patients' genotypes.
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